Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial

Overview of attention for article published in Lancet Oncology, December 2015

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (94th percentile)
High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

news: 2 news outlets
policy: 2 policy sources
twitter: 16 X users

facebook: 1 Facebook page
googleplus: 1 Google+ user

Citations

dimensions_citation: 138 Dimensions

Readers on

mendeley: 207 Mendeley

Summary News Policy documents X Facebook Google+ Dimensions citations

So far, Altmetric has seen 1 Google+ post.

360 medical, 08 Dec 2015

Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and... Bendamustine plus…

This page shows the most recent Google+ posts that mention this research output.

Click here to find out how to access more activity.